These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19287186)

  • 1. Improving vaccines by targeting antigens to dendritic cells.
    Shortman K; Lahoud MH; Caminschi I
    Exp Mol Med; 2009 Feb; 41(2):61-6. PubMed ID: 19287186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting antibody responses by targeting antigens to dendritic cells.
    Caminschi I; Shortman K
    Trends Immunol; 2012 Feb; 33(2):71-7. PubMed ID: 22153931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting human dendritic cells in situ to improve vaccines.
    Sehgal K; Dhodapkar KM; Dhodapkar MV
    Immunol Lett; 2014 Nov; 162(1 Pt A):59-67. PubMed ID: 25072116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells.
    Pugholm LH; Petersen LR; Søndergaard EK; Varming K; Agger R
    Scand J Immunol; 2015 Dec; 82(6):515-22. PubMed ID: 26346906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dendritic cells of mucosa and skin: "recruited for vaccination"].
    Le Borgne M; Dubois B; Kaiserlian D
    Med Sci (Paris); 2007 Oct; 23(10):819-25. PubMed ID: 17937889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.
    Tacken PJ; Figdor CG
    Semin Immunol; 2011 Feb; 23(1):12-20. PubMed ID: 21269839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
    Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
    Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells.
    Unger WW; van Kooyk Y
    Curr Opin Immunol; 2011 Feb; 23(1):131-7. PubMed ID: 21169001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugates.
    Mende I; Hoffmann P; Wolf A; Lutterbüse R; Kopp E; Baeuerle PA; de Baey A; Kufer P
    Int Immunol; 2005 May; 17(5):539-47. PubMed ID: 15778289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines.
    Klechevsky E; Liu M; Morita R; Banchereau R; Thompson-Snipes L; Palucka AK; Ueno H; Banchereau J
    Hum Immunol; 2009 May; 70(5):281-8. PubMed ID: 19236899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells and immune responses to orally administered antigens.
    Mowat AM
    Vaccine; 2005 Mar; 23(15):1797-9. PubMed ID: 15734044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.
    Hartung E; Becker M; Bachem A; Reeg N; Jäkel A; Hutloff A; Weber H; Weise C; Giesecke C; Henn V; Gurka S; Anastassiadis K; Mages HW; Kroczek RA
    J Immunol; 2015 Feb; 194(3):1069-79. PubMed ID: 25520399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.